INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 135 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2019. The put-call ratio across all filers is 2.11 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $315,000 | +67.6% | 12,256 | 0.0% | 0.00% | +50.0% |
| Q1 2020 | $188,000 | -97.5% | 12,256 | -94.4% | 0.00% | -97.3% |
| Q4 2019 | $7,494,000 | +406.7% | 218,415 | +10.4% | 0.07% | +311.1% |
| Q3 2019 | $1,479,000 | -2.4% | 197,927 | +69.6% | 0.02% | -14.3% |
| Q2 2019 | $1,515,000 | +13.5% | 116,684 | +6.5% | 0.02% | +10.5% |
| Q1 2019 | $1,335,000 | +62.8% | 109,584 | +52.2% | 0.02% | +35.7% |
| Q4 2018 | $820,000 | +255.0% | 72,014 | +577.8% | 0.01% | +366.7% |
| Q3 2018 | $231,000 | +1.3% | 10,625 | -17.8% | 0.00% | -25.0% |
| Q2 2018 | $228,000 | -6.2% | 12,920 | -23.0% | 0.00% | 0.0% |
| Q4 2017 | $243,000 | +32.1% | 16,770 | +43.7% | 0.00% | 0.0% |
| Q3 2017 | $184,000 | -87.6% | 11,670 | -78.1% | 0.00% | -87.1% |
| Q1 2016 | $1,480,000 | – | 53,224 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |